Kala Bio, INC 10-Q quarterly reports

Kala Bio's Q2 2026 report reveals significant operational losses and the discontinuation of its KPI-012 drug candidate, alongside a strategic shift towards an AI platform business.

KALA BIO reports Q1 2026 financial results while transitioning from a clinical-stage biopharmaceutical company to an AI platform-as-a-service provider.

KALA BIO, Inc. announced the failure of its key clinical trial, leading to a default on its primary loan, asset foreclosure by Oxford Finance, significant workforce reductions, and substantial doubt about its ability to continue as a going concern.

KALA BIO, Inc. reported significant losses and negative cash flows for Q2 2025, raising substantial doubt about its ability to continue as a going concern, despite progress in its KPI-012 clinical trial.

KALA BIO, Inc. announces its financial results for the first quarter of 2025, highlighting ongoing clinical trials for KPI-012 and expressing substantial doubt about its ability to continue as a going concern.

Kala Bio, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting ongoing clinical development of KPI-012 and its financial position.

Kala Bio, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical development of KPI-012 and recent financing activities.

Kala Bio reports a net loss of $11.8 million for the first quarter of 2024, focusing on the development of KPI-012 for persistent corneal epithelial defects.